Overall rank by patents
#230
Across all tracked assignees
USPTO PatentsView assignee record — 1,768 granted patents across 126 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
Novartis AG has been granted 1,768 US utility patents between 2015 and 2025, placing Novartis AG at rank #230 across all assignees tracked by PlainPatent. This portfolio spans 126 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.8 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Novartis AG is one of the broader-portfolio assignees in the PatentsView dataset. The composite Innovation Score of 63.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 570 grants, compared with 1,198 in the 2015–2019 window — a -52% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Novartis AG's 15.8 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a diversified footprint across 100+ CPC subclasses spreads risk across many technology fronts. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Novartis AG against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
International Business Machines Corporation
72,926 patents
Canon Kabushiki Kaisha
34,378 patents
LG ELECTRONICS INC.
32,607 patents
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
Apple Inc.
30,560 patents
QUALCOMM Incorporated
30,354 patents
Intel Corporation
27,498 patents
Novartis AG
1,768 patents
What this shows Novartis holds 1,768 patents — placing it at rank #230 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 229 | 13.0% |
| 2016 | 253 | 14.3% |
| 2017 | 270 | 15.3% |
| 2018 | 218 | 12.3% |
| 2019 | 228 | 12.9% |
| 2020 | 131 | 7.4% |
| 2021 | 120 | 6.8% |
| 2022 | 97 | 5.5% |
| 2023 | 72 | 4.1% |
| 2024 | 93 | 5.3% |
| 2025 | 57 | 3.2% |
Overall rank by patents
#230
Across all tracked assignees
63.9 out of 100
Novartis AG's primary CPC class — all holders and yearly trends
See where Novartis AG ranks among the largest US patent assignees
Browse every CPC technology area by patent activity
The four dimensions behind the Innovation Score
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.